Satellos Expands Leadership Team with New CFO Appointment
- Elizabeth Williams brings extensive expertise in corporate finance and strategy for biotech companies listed on Nasdaq and TSX.
- The appointment of Williams strengthens the leadership team and supports the advancement of a small molecule drug candidate for Duchenne muscular dystrophy.
- None.
- Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX.
- Current CFO, Warren Whitehead, CPA, CMA, transitions to Head of Corporate Strategy to focus on strengthening and expanding collaborations and partnerships.
- Satellos is advancing a potentially first-in-class small molecule drug candidate to clinical trials for Duchenne muscular dystrophy.
Toronto, Ontario--(Newsfile Corp. - September 5, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the appointment of Elizabeth (Liz) Williams, CPA, CA, as Chief Financial Officer (CFO). Warren Whitehead, CPA, CMA, who has served as CFO for Satellos for two years, will now become Head of Corporate Strategy. These management updates were effective as of September 1, 2023.
Frank Gleeson, Co-founder and CEO of Satellos, said, "Warren's depth of experience has guided Satellos through our key financial milestones, from going public in 2021 to our recent CA
"With the company's recent financing, Satellos has the support and confidence of a high-quality group of healthcare-focused investors," said Ms. Williams. "Satellos is making significant progress in advancing a small molecule drug candidate for Duchenne muscular dystrophy that has the potential to be a meaningful therapeutic approach complementary to genetic medicines. I look forward to supporting the advancement of this leading program to the clinic."
Elizabeth Williams, CPA, CA
Ms. Williams has nearly 20 years of experience in biotech, working with publicly listed entities in both Canada and the United States. Prior to joining Satellos, Ms. Williams was CFO of Medicenna (NASDAQ: MDNA), where she was responsible for all financial, legal, and investor relations functions and led the graduation of the company from the TSXV to the TSX main board and subsequently the Nasdaq. Previous to Medicenna, she was Vice President of Finance and Administration at Aptose Biosciences Inc. (NASDAQ: APTO), previously Lorus Therapeutics Inc., a biotechnology company listed on both the TSX and Nasdaq capital markets. While at Aptose, Ms. Williams held several positions, including Acting CFO, and was responsible for a broad range of activities including financings, financial reporting, and regulatory compliance. She serves as Director and Chair of the Audit Committee of Triumvira Immunologics Inc. Ms. Williams is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA).
Warren Whitehead, CPA, CMA
Mr. Whitehead has more than 30 years of experience in senior financial management positions for publicly traded biotechnology and pharmaceutical companies. Previously, he served as CFO of ProMIS Neurosciences Inc. (NASDAQ: PMN), formerly Amorfix Life Sciences Ltd. Prior to ProMIS, he was CFO of ARIUS Research Inc., a TSX-listed company, where he provided financial guidance and leadership during the acquisition by Roche. Prior to that, he was CFO of Labopharm Inc., where he completed a series of public equity financings, including a cross-border Nasdaq offering. Other leadership experience includes CFO of Resolution Pharmaceuticals Inc. and a position in finance and business development at Glaxo Canada (now GlaxoSmithKline). Mr. Whitehead currently serves as Director and Chair of the Audit Committee of Aptose Biosciences. Mr. Whitehead is a CPA and Certified Management Accountant (CMA).
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body's innate muscle repair and regeneration process. The Company's lead drug candidate, SAT-3153, is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com.
Contacts:
Business Development: Ryan Mitchell, Ph.D., rmitchell@satellos.com
Communications: Christina Cameron, ccameron@satellos.com, +1.647.660.1780
For Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091
Notice on Forward-Looking Statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the anticipated benefits to patients from a small molecule treatment for Duchenne; the general benefits of modulating stem cell polarity by administering small molecule drugs; its/their prospective impact on Duchenne patients and muscle regeneration generally; the utility of regenerating muscle by modulating polarity; adoption of Satellos' approach by the medical community; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are "forward-looking information or statements." Often but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "anticipate", "believe", "plan", "expect", "intend", "estimate", "anticipate", "potential", "prospective" , "assert" or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, and those risks listed in the "Risk Factors" section of Satellos' prospectus dated May 9, 2023 and Satellos' Annual Information Form dated April 27, 2023 (both of which are on Satellos' profile at www.sedarplus.ca). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/179361
